dc.contributor.author | Erdiş E. | |
dc.contributor.author | Karahan O. | |
dc.contributor.author | Manduz Ş. | |
dc.contributor.author | Özdemir Ö. | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T09:31:15Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T09:31:15Z | |
dc.date.issued | 2010 | |
dc.identifier.issn | 1306-7656 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/5135 | |
dc.description.abstract | Objective: Deep vein thrombosis (DVT) is a common and troubled disease that can result in higher rates of morbidity and mortality if not diagnosed and treated carefully. The basic hypothesis on etiology of DVT is that most patients who complain idiopathic DVT have a genetic predisposition, which remains subclinical until an extra stress occurs. Cancer is another important risk factor for DVT. Cancer and its treatment can affect all three arms of Virchow's classical triad of causation of thromboembolic disease: alteration in blood flow (by creating mass), damage of endothelial cells, and trigger of procoagulants. In this study we aimed to observe the differences of prothrombotic gene polymorphisms in DVT cases with lung cancer versus DVT cases without cancer. Material and Methods: All cases with DVT were evaluated in terms of cancer. Cases were divided in two groups, the first with 33 patients that had DVT with lung cancer and the second with 63 patients that had DVT without cancer. We studied prothrombotic gene profile in each two group. Therefore we detected the prevalence of prothrombin G20210A, factor V G1691A (factor V Leiden), methylenetetrahydrofolate reductase (MTHFR) C677T and MTHFR A1298C, angiotensin converting enzyme (ACE), plasminogen activator inhibitor-1 (PAI-1), Glycoprotein IIIa gene polymorphisms, which are known cause thrombosis in our study groups. Results: We found that homozygote gene polymorphisms of PAI-1 (PAI-1 4G/4G) were significantly higher in cancer patients with DVT (x2=9.41 p=0.002). Furthermore, no significant difference was observed between genotypes for prothrombin G20210A, factor V Leiden, MTHFR C677T and MTHFR A1298C, ACE, Glycoprotein IIIa gene polymorphisms. Conclusion: The gene polymorphism of homozygote PAI-1 (PAI-1 4G/4G) may be an important risk factor for DVT patients with lung cancer. However detection of no significant difference between two groups in terms of other prothrombotic gene polymorphisms suggests other genes together with non-genetic factors. Copyright © 2010 by Türkiye Klinikleri. | en_US |
dc.description.sponsorship | Karahan, O.; Kalp ve Damar Cerrahisi AD, Cumhuriyet Üniversitesi Tip Fakültesi, Sivas, Turkey; email: oguzk2002@gmail.com | en_US |
dc.language.iso | tur | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | Genetic | en_US |
dc.subject | Genetic predisposition to disease | en_US |
dc.subject | Lung neoplasms | en_US |
dc.subject | Polymorphism | en_US |
dc.subject | Venous thrombosis | en_US |
dc.title | The differences of prothrombotic gene polymorphism in deep venous thrombosis cases with lung cancer [Akci?er kanserli derin ven trombozu olgularinda protrombotik gen polimorfizmi farkliliklari] | en_US |
dc.type | article | en_US |
dc.relation.journal | Turkiye Klinikleri Cardiovascular Sciences | en_US |
dc.contributor.department | Erdiş, E., Radyasyon Onkolojisi AD, Cumhuriyet Üniversitesi Tip Fakültesi, Sivas, Turkey -- Karahan, O., Kalp ve Damar Cerrahisi AD, Cumhuriyet Üniversitesi Tip Fakültesi, Sivas, Turkey -- Manduz, Ş., Kalp ve Damar Cerrahisi AD, Cumhuriyet Üniversitesi Tip Fakültesi, Sivas, Turkey -- Özdemir, Ö., Tibbi Genetik AD, Cumhuriyet Üniversitesi Tip Fakültesi, Sivas, Turkey | en_US |
dc.identifier.volume | 22 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.endpage | 60 | en_US |
dc.identifier.startpage | 54 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |